Effects of insulin-like growth factors and insulin-like growth factor binding protein-2 on the in vitro proliferation of peripheral blood mononuclear cells

Hettmer, Simone; Dannecker, Luciana; Foell, Juergen; Elmlinger, Martin W.; Dannecker, Guenther E.

doi:10.1016/j.humimm.2004.10.014

Cited by 24 publications

(24 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increase of IGFBP-2 expression might be directly correlated to the increased cell proliferation rate. 31 Hettmer et al 32 recently published data demonstrating that incubation with exogenous IGFBP-2 increased the proliferation of PBMC; whereas, anti-IGFBP-2 had an antiproliferative effect on PBMC that was reversed by simultaneous exposure to IGFBP-2. These data strongly suggest a role for IGFBP-2 as a local growth factor contributing to the proliferation and activation of mononuclear cells.…”

Section: Discussionmentioning

confidence: 99%

“…These data strongly suggest a role for IGFBP-2 as a local growth factor contributing to the proliferation and activation of mononuclear cells. 32 The continuous increase of IGFBP-2 levels in the first weeks after transplantation are associated with the proliferation and differentiation of the graft cells and may be involved in the bone marrow recovery. The disease recurrence after transplantation is associated with a high proliferation rate of leukemic cells, expecting higher IGFBP-2 levels in patients developing a relapse.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML

Dawczynski

Kauf

Schlenvoigt

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Insulin-like growth factor binding protein (IGFBP)-2 has mitogenic effects in normal and neoplastic cells. The purpose of this study is to examine the diagnostic and prognostic significance of elevated IGFBP-2 levels in children with AML after hematopoietic stem cell transplantation (HSCT) at relapse and continuous complete remission (CCR). In 27 children with AML (mean age 13.675.3 years; patients in remission n ¼ 15 with relapse n ¼ 12) serum parameters of IGFBP-2, IGFBP-3, IGF-I and IGF-II were analyzed up to 18 months after HSCT by RIA. AML-patients with evidence of relapse demonstrated a continuous increase of IGFBP-2 levels during the follow-up. At day 100 after HSCT, IGFBP-2 concentrations were significantly higher in patients with relapse than in children without relapse (7.474.0 standard deviation score (SDS) vs 3.971.7 SDS; P ¼ 0.01). Serum IGFBP-2 was identified as an independent factor for the prediction of relapse. Furthermore, the probability of relapse-free survival (RFS) in patients with IGFBP-2 44.5 SDS at day 100 after HSCT was 31% compared to patients with IGFBP-2 o4.5 SDS was 72% (P ¼ 0.004). Patients with IGFBP-2 concentration up to 4.5 SDS more likely developed a relapse and had a poorer outcome. Identification of these patients allows a more individualized and aggressive adjuvant treatment and follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML

Dawczynski

Kauf

Schlenvoigt

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Administration of IGF-1 increases the circulating pool of CD4 ϩ T cells and splenic B cells in mice (10,11), suggesting a role for this growth factor in myelopoietic cell expansion (12). It promotes T cell proliferation during early activation (13) and inhibits apoptosis of both immature and mature T cells through at least three distinct mechanisms (14,15). IGF-1 stimulates inflammatory cytokine production in T cells and monocytes, including IL-2 (16), TNF-␣ (17), and IL-8 (18).…”

mentioning

confidence: 99%

Aberrant Expression of the Insulin-Like Growth Factor-1 Receptor by T Cells from Patients with Graves’ Disease May Carry Functional Consequences for Disease Pathogenesis

Douglas

Gianoukakis

Kamat

et al. 2007

The Journal of Immunology

133

View full text Add to dashboard Cite

Graves’ disease (GD), an autoimmune process involving thyroid and orbital tissue, is associated with lymphocyte abnormalities including expansion of memory T cells. Insulin-like growth factor receptor-1 (IGF-1R)-bearing fibroblasts overpopulate connective tissues in GD. IGF-1R on fibroblasts, when ligated with IgGs from these patients, results in the expression of the T cell chemoattractants, IL-16 and RANTES. We now report that a disproportionately large fraction of peripheral blood T cells express IGF-1R (CD3+IGF-R+). CD3+IGF-1R+ T cells comprise 48 ± 4% (mean ± SE; n = 33) in patients with GD compared with 15 ± 3% (n = 21; p < 10−8) in controls. This increased population of IGF-1R+ T cells results, at least in part, from an expansion of CD45RO+ T cells expressing the receptor. In contrast, the fraction of CD45RA+IGF-1R+ T cells is similar in GD and controls. T cells harvested from affected orbital tissues in GD reflect similar differences in the proportion of IGF-1R+CD3+ and IGF-1R+CD4+CD3+ cells as those found in the peripheral circulation. GD-derived peripheral T cells express durable, constitutive IGF-1R expression in culture and receptor levels are further up-regulated following CD3 complex activation. IGF-1 enhanced GD-derived T cell incorporation of BrdU (p < 0.02) and inhibited Fas-mediated apoptosis (p < 0.02). These findings suggest a potential role for IGF-1R displayed by lymphocytes in supporting the expansion of memory T cells in GD.

show abstract

“…Within PWM dose, columns with different letters differ (PB0.05). thymus weights and subsequent increases in antibody response (Clark, 1997;Hettmer, Dannecker, Foell, Elmlinger, & Dannecker, 2005;Robbins et al, 1994). The increases in lymphocyte number were apparent for up to three weeks following cessation of IGF-1 treatment.…”

Section: Discussionmentioning

confidence: 99%

Insulin-like growth factor-1 attenuates glucocorticoid suppression of pig lymphocyte function

Collier

Welsh

Carroll

et al. 2011

Food and Agricultural Immunology

View full text Add to dashboard Cite

This study evaluated the effects of dexamethasone and insulin-like growth factor-1 on mitogen-induced lymphocyte immune-associated activities including metabolic reduction of the tetrazolium salt and immunoglobulin (Ig) production. Peripheral blood lymphocytes were isolated from blood samples obtained from three 6-week-old male pigs and plated in triplicate for treatment and dose (n 09 wells/treatment/dose). Cells were stimulated with specific doses and combinations of concanavalin A (ConA), pokeweed mitogen (PWM), DEX and/or IGF-1. Both Con A and PWM induced dose-dependent increases (PB0.05) in lymphocyte metabolism and IgM production. Lymphocyte metabolism and IgM production induced by submaximal concentrations of ConA and PWM were dosedependently suppressed (P B0.05) by DEX. Treatment with IGF-1 attenuated (P B0.5) the suppressive effects of DEX on ConA-but not PWM-induced lymphocyte metabolism. The addition of IGF-1 reduced (PB0.05) DEX suppression of ConA-and PWM-induced IgM production. These results demonstrate that IGF-1 can differentially reduce the suppressive effects of DEX on lymphocytes dependent on mitogen type.

show abstract

Effects of insulin-like growth factors and insulin-like growth factor binding protein-2 on the in vitro proliferation of peripheral blood mononuclear cells

Cited by 24 publications

References 35 publications

Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML

Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML

Aberrant Expression of the Insulin-Like Growth Factor-1 Receptor by T Cells from Patients with Graves’ Disease May Carry Functional Consequences for Disease Pathogenesis

Insulin-like growth factor-1 attenuates glucocorticoid suppression of pig lymphocyte function

Contact Info

Product

Resources

About